Depatment of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-15, Showa-machi, Maebashi, Gunma 371-8511, Japan.
Department of Radiation Oncology, Fukushima Medical University, 1, Hikarigaoka, Fukushima, Fukushima 960-1247, Japan.
J Radiat Res. 2020 Mar 23;61(2):275-284. doi: 10.1093/jrr/rrz106.
The current study aimed to evaluate the outcomes of patients with adenocarcinoma (AC) of the uterine cervix after definitive radiotherapy (RT) and to evaluate prognostic factors, including immunity-related molecules. A total of 71 patients with AC of the uterine cervix from multiple Japanese institutions were retrospectively analysed. Histological subtypes were diagnosed according to the 2014 World Health Organization classification. All patients underwent definitive RT comprising external beam RT and intracavitary brachytherapy with or without concurrent chemotherapy. Immunohistochemical studies were performed to detect the expression of programmed cell death-ligand 1(PD-L1) and CD8. The 5-year locoregional control (LC), overall survival (OS) and progression-free survival (PFS) rates for all patients were 61.8, 49.7 and 36.1%, respectively. The LC, OS and PFS rates were not significantly different among the histological subtypes. Membranous PD-L1 expression was not significantly associated with prognosis. Patients with CD8-positive tumor-infiltrating lymphocytes (CD8+TILs) in the tumor nests had significantly better OS than patients without CD8+TILs in the tumor nests (5-year OS: 53.8 vs 23.8%, P = 0.038). As expected, the International Federation of Gynecology and Obstetrics (FIGO) stage (2008) III-IVA and maximum tumor diameter > 40 mm were significantly associated with worse prognosis. In summary, the presence of CD8+TILs in the tumor nests has the potential to be an independent favorable prognostic factor for patients with AC of the uterine cervix after definitive RT.
本研究旨在评估接受根治性放疗(RT)的宫颈癌腺癌(AC)患者的结局,并评估包括免疫相关分子在内的预后因素。回顾性分析了来自多家日本机构的 71 例宫颈癌 AC 患者。组织学亚型根据 2014 年世界卫生组织分类进行诊断。所有患者均接受了包括外照射 RT 和腔内近距离放疗在内的根治性 RT,并辅以同期化疗。进行免疫组织化学研究以检测程序性细胞死亡配体 1(PD-L1)和 CD8 的表达。所有患者的 5 年局部区域控制(LC)、总生存(OS)和无进展生存(PFS)率分别为 61.8%、49.7%和 36.1%。组织学亚型之间的 LC、OS 和 PFS 率无显著差异。膜 PD-L1 表达与预后无显著相关性。肿瘤巢中 CD8+肿瘤浸润淋巴细胞(CD8+TILs)阳性的患者 OS 明显优于肿瘤巢中无 CD8+TILs 的患者(5 年 OS:53.8% vs 23.8%,P=0.038)。与预期一致,国际妇产科联合会(FIGO)分期(2008 年)III-IVA 和最大肿瘤直径>40mm 与预后较差显著相关。综上所述,肿瘤巢中存在 CD8+TILs 可能是宫颈癌 AC 患者接受根治性 RT 后的独立有利预后因素。